Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This study reported that combining fexofenadine or ebastine with topical therapy significantly improved hair regrowth and reduced the severity of alopecia areata over 12 weeks compared to topical treatment alone.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

In this case study, a 19-year-old woman with Henoch-Schönlein purpura, potentially triggered by hepatitis B vaccination, experienced improved symptoms after correcting low vitamin D levels and undergoing tonsillectomy, demonstrating these interventions may benefit similar patients.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This article discusses multiple minute digitate hyperkeratosis in a dermatological context and reports no new clinical findings; the authors focus on a descriptive review.

This study assessed the effectiveness of the EQ-5D in measuring health-related quality of life for alopecia areata patients and found it may not accurately capture the burden of the condition, particularly its psychosocial impact, compared to other more condition-specific measures.

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This study located a potential genetic link for androgenetic alopecia on chromosome 3q26, marking an early step in identifying new susceptibility genes for male pattern baldness.

This study reviews the epidemiology of alopecia areata in the UK, focusing on its links to mental health comorbidities, autoimmune/atopic associations, and common infection incidences.

In this study, the researchers observed that male pattern alopecia is characterized by miniature follicles, enlarged sebaceous glands, and an increased number of mast cells, without significant abnormalities in enzyme activity.

This study found that serum calcium, serum ferritin, and vitamin D3 levels were lower in students with premature graying of hair compared to controls, suggesting a potential role in the condition.

This study suggests that increased activity of the histamine synthesizing enzyme histidine decarboxylase may play a role in initiating the anagen phase of hair regrowth in mice.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

The conclusion is that small hair follicles cause baldness in macaques, and treatments like antiandrogens and minoxidil can prevent hair loss and promote regrowth.

This study observed that tryptophan levels in human hair are higher in males than females, increase with age, and vary with hair color, being highest in grey and white hair.